Improving viral vector safety for gene therapies
Drug Discovery World
AUGUST 21, 2024
Integrating vectors such as lentivirus stably insert their payload into the host cell genome, which is advantageous for long-term treatment. Depending on the delivery mechanism, the therapeutic gene product may or may not integrate into the genome. The frequency of AAV integration has been estimated at 0.1% to 10% in hepatocytes.
59 
Let's personalize your content